Assy, M., El Ashmawy, H., Soliman, J., Abd El Hamed, A. (2020). Osteopontin As A Marker of Diabetic Nephropathy in Patients With Type 2 Diabetes Mellitus. The Egyptian Journal of Hospital Medicine, 81(7), 2439-2444. doi: 10.21608/ejhm.2020.133956
Mohammed Hamdy Assy; Hazem Mohamed El Ashmawy; Jehan Saeed Abdo Soliman; Alaa Badr Abd El Hamed. "Osteopontin As A Marker of Diabetic Nephropathy in Patients With Type 2 Diabetes Mellitus". The Egyptian Journal of Hospital Medicine, 81, 7, 2020, 2439-2444. doi: 10.21608/ejhm.2020.133956
Assy, M., El Ashmawy, H., Soliman, J., Abd El Hamed, A. (2020). 'Osteopontin As A Marker of Diabetic Nephropathy in Patients With Type 2 Diabetes Mellitus', The Egyptian Journal of Hospital Medicine, 81(7), pp. 2439-2444. doi: 10.21608/ejhm.2020.133956
Assy, M., El Ashmawy, H., Soliman, J., Abd El Hamed, A. Osteopontin As A Marker of Diabetic Nephropathy in Patients With Type 2 Diabetes Mellitus. The Egyptian Journal of Hospital Medicine, 2020; 81(7): 2439-2444. doi: 10.21608/ejhm.2020.133956
Osteopontin As A Marker of Diabetic Nephropathy in Patients With Type 2 Diabetes Mellitus
Department of Internal Medicine, Faculty of Medicine – Zagazig University
Abstract
Background: Diabetic nephropathy is the most common cause of end stage renal disease (ESRD) that is associated with high rates of morbidity and mortality. osteopontin (OPN) is a secreted phosphorylated glycoprotein that mediates diverse biological functions. Objective: The study aimed to determine the relation between serum OPN and the progression of diabetic nephropathy in patients with type 2 DM. That may open a door for early prediction of diabetic nephropathy. Patients and Methods: This case-control study was conducted in Internal Medicine, Endocrinology Unit and Biochemistry Departments, Zagazig University Hospital. This study was carried out on 96 patients devided into: Group 1: 20 age and sex matched healthy volunteers (control group). Group 2: 38 patients with type 2 DM without nephropathy (DWN group). Group3: 38 patients with type 2 DM with nephropathy (DN group). Serum osteopontin concentrations was measured for all cases. Results: HOMA-IR increased significantly in DN group (8.59 ± 1.34) compared to DWN group (4. 73 ± 0.59) and control group (0.90 ± 0.18). Serum osteopontin level (ng/ml) increased significantly in the DN group (258.52 ± 46.93 ng/ml) compared to DWN group (159.12 ± 19.56 ng/ml) and control group (70.90 (± 20.47 ng/ml)(p value =0.000). There was a high significant correlation between S. OPN and HOMA-IR. Conclusion: Type 2 diabetic patients with or without nephropathy showed increased osteopontin levels than control group. Serum osteopontin may be considered as an early prognostic marker for the risk of nephropathy in patients with type 2 diabetes mellitus.
View on SCiNiTO
Top